Given its immunopathogenic role, IL-18 may be considered as a promising biomarker of COVID-19 severity, and therapeutic strategies targeting IL-18 inhibition, such as neutralization with IL-18 binding protein, may offer clinical benefits in severe cases [89]. Here, IL18 is linked to COVID-19.